Fajumi J O
Br J Cancer. 1980 Feb;41(2):183-8. doi: 10.1038/bjc.1980.28.
The surface properties of blood lymphocytes from treated myeloma patients and healthy controls were studied in vitro. The patients were tested 6 weeks after the last treatment to allow time for cells to recovery from possible drug toxicity. Peripheral-blood lymphocytes were tested for rosette formation with unsensitized sheep erythrocytes (E rosettes) and with complement and antibody-coated erythrocytes (EAC rosettes). The tests were duplicated using lymphocytes pretreated with trypsin. As others have noted, myelomatosis is associated with increased blood levels of EAC-rosette-forming cells and a marked reduction in E-rosette-forming cells. E-rosette formation was significantly increased by pretreatment of myeloma lymphocytes with trypsin. By contrast, enzyme-treated cells showed no significant change in EAC-rosette formation. These results suggest that the absolute number of circulating T cells is probably not reduced in myelomatosis, but that the surface of T cells is somehow modified so that a proportion of them lose the ability to form E rosettes.
对接受治疗的骨髓瘤患者和健康对照者的血液淋巴细胞的表面特性进行了体外研究。在最后一次治疗6周后对患者进行检测,以便细胞有时间从可能的药物毒性中恢复。对外周血淋巴细胞进行检测,观察其与未致敏绵羊红细胞形成的玫瑰花结(E玫瑰花结)以及与补体和抗体包被红细胞形成的玫瑰花结(EAC玫瑰花结)。使用经胰蛋白酶预处理的淋巴细胞重复进行这些检测。正如其他人所指出的,骨髓瘤与血液中EAC玫瑰花结形成细胞水平升高以及E玫瑰花结形成细胞显著减少有关。用胰蛋白酶预处理骨髓瘤淋巴细胞可使E玫瑰花结形成显著增加。相比之下,经酶处理的细胞在EAC玫瑰花结形成方面无显著变化。这些结果表明,骨髓瘤患者循环T细胞的绝对数量可能并未减少,但T细胞表面以某种方式发生了改变,以至于其中一部分失去了形成E玫瑰花结的能力。